Immuneering Reveals Data From Three Pancreatic Cancer Arms In Phase 2a Trial Of IMM-1-104; Announces Plans For Trial Expansion With Additional Arms

Benzinga · 01/07 12:06

- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway -

- Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) -

- Encouraging initial data for IMM-1-104 monotherapy in second-line pancreatic cancer, including a 67% reduction (PR), demonstrate activity and support development in first-line combinations; over 75 patients enrolled across all three Phase 2a pancreatic arms -

- Continued highly differentiated tolerability profile observed for IMM-1-104;

approved MEK inhibitors currently drive ~$2.4 billion in sales -

- Further IMM-1-104 Phase 2a data expected in 2Q'25; additional combination arms planned to be initiated in 2025 -